-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Aardvark Therapeutics, Lowers Price Target to $18

Benzinga·11/14/2025 15:37:12
Listen to the news
RBC Capital analyst Brian Abrahams maintains Aardvark Therapeutics (NASDAQ:AARD) with a Outperform and lowers the price target from $19 to $18.